Literature DB >> 26113011

RS3PE: Clinical and Research Development.

Hongbin Li1, Roy D Altman, Qingping Yao.   

Abstract

Remitting seronegative symmetrical synovitis with pitting edema or RS3PE is a rare elderly-onset rheumatic syndrome. Although there are overlapping clinical manifestations between RS3PE, elderly-onset rheumatoid arthritis, and polymyalgia rheumatica, RS3PE has distinct characteristics. RS3PE can be associated with neoplasia and various rheumatic conditions, suggesting that it may be heterogeneous, and is considered as a paraneoplastic rheumatic disease. The pathogenesis of RS3PE may involve vascular endothelial growth factor and infection in RS3PE based upon limited data. Patients with RS3PE without concomitant malignancy respond well to small doses of glucocorticoids and carry good prognosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26113011     DOI: 10.1007/s11926-015-0525-0

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  65 in total

Review 1.  Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome: a review of the literature and a report of three cases.

Authors:  J A Finnell; I A Cuesta
Journal:  J Foot Ankle Surg       Date:  2000 May-Jun       Impact factor: 1.286

Review 2.  Gastric carcinoma in association with remitting seronegative symmetrical synovitis with pitting edema.

Authors:  A Ethiopia; D Bell
Journal:  J Rheumatol       Date:  1999-05       Impact factor: 4.666

3.  Remitting symmetric seronegative synovitis with pitting edema (RS3PE) secondary to non-Hodgkin's lymphoma.

Authors:  K Goldenberg; M Rozenbaum; I Rosner; J Naschitz; C Kotler
Journal:  Clin Exp Rheumatol       Date:  1998 Nov-Dec       Impact factor: 4.473

4.  Remitting seronegative symmetrical synovitis with pitting oedema associated with chronic lymphocytic leukaemia.

Authors:  M Ekenel; S Yavuz; S Karti; H Direskeneli; T Akoğlu
Journal:  Clin Rheumatol       Date:  2000       Impact factor: 2.980

Review 5.  Rheumatoid arthritis in the elderly.

Authors:  C P Mavragani; H M Moutsopoulos
Journal:  Exp Gerontol       Date:  1999-06       Impact factor: 4.032

Review 6.  Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond.

Authors:  Kriti Mittal; John Ebos; Brian Rini
Journal:  Semin Oncol       Date:  2014-02-28       Impact factor: 4.929

Review 7.  Paraneoplastic syndromes in rheumatology.

Authors:  Bernhard Manger; Georg Schett
Journal:  Nat Rev Rheumatol       Date:  2014-08-19       Impact factor: 20.543

8.  Remitting seronegative symmetrical synovitis with pitting oedema in a patient with myelodysplastic syndrome and relapsing polychondritis.

Authors:  P Manganelli; G Delsante; G Bianchi; P Fietta; F Quaini
Journal:  Clin Rheumatol       Date:  2001       Impact factor: 2.980

Review 9.  Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis?

Authors:  Qingping Yao; Xiangqian Su; Roy D Altman
Journal:  Semin Arthritis Rheum       Date:  2009-02-13       Impact factor: 5.532

10.  A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort.

Authors:  Rachael L Gross; Julie S Schwartzman-Morris; Michael Krathen; George Reed; Hong Chang; Katherine C Saunders; Mark C Fisher; Jeffrey D Greenberg; Chaim Putterman; Philip J Mease; Alice B Gottlieb; Joel M Kremer; Anna Broder
Journal:  Arthritis Rheumatol       Date:  2014-06       Impact factor: 10.995

View more
  14 in total

1.  Remitting seronegative symmetric synovitis with pitting edema (RS3PE) with painful erythematous nodules.

Authors:  Nicholas Kevin Laidler; Thomas Delaney
Journal:  BMJ Case Rep       Date:  2020-04-22

Review 2.  Hematological malignancies mimicking rheumatic syndromes: case series and review of the literature.

Authors:  Gil Bornstein; Nadav Furie; Nimrod Perel; Ilan Ben-Zvi; Chagai Grossman
Journal:  Rheumatol Int       Date:  2018-07-18       Impact factor: 3.580

3.  Polymyalgia Rheumatica in Association with Remitting Seronegative Sinovitis with Pitting Edema: a Neoplastic Warning.

Authors:  Ciro Manzo; Maria Natale
Journal:  Can Geriatr J       Date:  2017-06-30

4.  Remitting Seronegative Symmetrical Synovitis with Pitting Oedema as the First Manifestation of an Adenocarcinoma of the Caecum.

Authors:  Edgar Pratas; João Carvalho; Isabel Domingues; João Fonseca; Teresa Carvalho; Gabriela Sousa; Manuel Teixeira Veríssimo
Journal:  Eur J Case Rep Intern Med       Date:  2018-12-27

5.  Remitting symmetrical seronegative synovitis and pitting edema syndrome with concomitant adenocarcinoma of the lung.

Authors:  S Karahan
Journal:  J Postgrad Med       Date:  2019 Jul-Sep       Impact factor: 1.476

6.  bFGF could be a biomarker of malignancy in RS3PE syndrome: an ambispective single-center cohort analysis of 51 patients.

Authors:  Yuzhou Gan; Yi Sun; Jiayang Jin; Yifan Wang; Jiali Chen; Yukchiu Chung; Xue Li; Hua Ye
Journal:  Arthritis Res Ther       Date:  2021-10-15       Impact factor: 5.156

7.  Remitting seronegative symmetrical synovitis with pitting oedema after surgical remission of Cushing's syndrome.

Authors:  Hiroaki Iwasaki; Hitomi Kanno; Shi-Xu Jiang
Journal:  BMJ Case Rep       Date:  2020-03-31

8.  The combined prevalence of classified rare rheumatic diseases is almost double that of ankylosing spondylitis.

Authors:  Judith Leyens; Tim Th A Bender; Martin Mücke; Christiane Stieber; Dmitrij Kravchenko; Christian Dernbach; Matthias F Seidel
Journal:  Orphanet J Rare Dis       Date:  2021-07-22       Impact factor: 4.123

9.  SAPHO Syndrome Masquerading as Metastatic Breast Cancer.

Authors:  Devin Malik; Richa Handa; Andrew Petraszko; Sheela Tejwani
Journal:  Case Rep Rheumatol       Date:  2018-03-20

10.  New onset of remitting seronegative symmetrical synovitis with pitting oedema and palmoplantar psoriasis flare-up after Sars-Cov-2 vaccination.

Authors:  L Quattrini; L Verardi; G Caldarola; G Peluso; C De Simone; M D'Agostino
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-07-23       Impact factor: 9.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.